miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9 Retraction in /10.3892/or.2021.8233

Li,Zhihong; Li,Bai; Niu,Liang; Ge,Liang

doi:10.3892/or.2016.5275

miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9

Retraction in: /10.3892/or.2021.8233

Authors:
- Zhihong Li
- Bai Li
- Liang Niu
- Liang Ge
View Affiliations

Affiliations: Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Colorectal and Anal Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Operating Room, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Anesthesiology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: November 25, 2016 https://doi.org/10.3892/or.2016.5275
Pages: 297-304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A growing body of evidence suggests that microRNA-592 (miR-592) may be involved in the initiation and progression of cancer by targeting various molecules in several human cancers. However, the function and underlying molecular mechanism of miR-592 in non-small cell lung cancer (NSCLC) remains unclear. In the present study, we found that miR-592 was significantly downregulated in NSCLC cell lines and tissues by real-time quantitative RT-PCR (qRT-PCR), and that lower miR-592 expression was negatively associated with advanced tumor/nodes/metastasis (TNM) classification stages (P<0.01) and lymph node metastasis (P<0.01). Function assay demonstrated that the miR-592 mimic reduced in vitro cell proliferation, colony formation, migration and invasion in A549 cells (a NSCLC-derived cell line), and inhibited in vivo tumor cell growth in xenografted nude mice. Furthermore, the gender determining region Y (SRY)-related high mobility group box 9 (SOX9) was confirmed as a direct target of miR-592, using luciferase reporter, qRT-PCR and western blot assays. Enforced overexpression of SOX9 effectively reversed the tumor suppressive functions of miR-592 on NSCLC proliferation, colony formation, migration and invasion. These findings suggested that miR-592 functions as tumor suppressor in NSCLC by suppressing the activity of SOX9, and that miR-592 might serve as a promising therapeutic target for NSCLC treatment.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Schabath MB, Nguyen A, Wilson P, Sommerer KR, Thompson ZJ and Chiappori AA: Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer. 86:14–21. 2014. View Article : Google Scholar : PubMed/NCBI
3	Uramoto H and Tanaka F: Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res. 3:242–249. 2014.PubMed/NCBI
4	Li C and Hong W: Research status and funding trends of lung cancer biomarkers. J Thorac Dis. 5:698–705. 2013.PubMed/NCBI
5	Guo H, Ingolia NT, Weissman JS and Bartel DP: Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
6	Fabian MR, Sonenberg N and Filipowicz W: Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
7	McManus MT: MicroRNAs and cancer. Semin Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Farazi TA, Spitzer JI, Morozov P and Tuschl T: miRNAs in human cancer. J Pathol. 223:102–115. 2011. View Article : Google Scholar : PubMed/NCBI
10	Skrzypski M, Dziadziuszko R and Jassem J: MicroRNA in lung cancer diagnostics and treatment. Mutat Res. 717:25–31. 2011. View Article : Google Scholar : PubMed/NCBI
11	Boeri M, Sestini S, Fortunato O, Verri C, Suatoni P, Pastorino U and Sozzi G: Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging. Expert Rev Mol Diagn. 15:801–813. 2015.PubMed/NCBI
12	Guan P, Yin Z, Li X, Wu W and Zhou B: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 31:542012.doi: 10.1186/1756-9966-31-54. View Article : Google Scholar : PubMed/NCBI
13	Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu X, Cho WC and Yang Y: An oncogenic role of miR-592 in tumorigenesis of human colorectal cancer by targeting Forkhead Box O3A (FoxO3A). Expert Opin Ther Targets. 20:771–782. 2016. View Article : Google Scholar : PubMed/NCBI
14	Jia YY, Zhao JY, Li BL, Gao K, Song Y, Liu MY, Yang XJ, Xue Y, Wen AD and Shi L: miR-592/WSB1/HIF-1α axis inhibits glycolytic metabolism to decrease hepatocellular carcinoma growth. Oncotarget. 7:35257–35269. 2016.PubMed/NCBI
15	Li X, Zhang W, Zhou L, Yue D and Su X: MicroRNA-592 targets DEK oncogene and suppresses cell growth in the hepatocellular carcinoma cell line HepG2. Int J Clin Exp Pathol. 8:12455–12463. 2015.PubMed/NCBI
16	Liu M, Zhi Q, Wang W, Zhang Q, Fang T and Ma Q: Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomed Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
17	Liu Z, Wu R, Li G, Sun P, Xu Q and Liu Z: MiR-592 inhibited cell proliferation of human colorectal cancer cells by suppressing of CCND3 expression. Int J Clin Exp Med. 8:3490–3497. 2015.PubMed/NCBI
18	Lv Z, Rao P and Li W: MiR-592 represses FOXO3 expression and promotes the proliferation of prostate cancer cells. Int J Clin Exp Med. 8:15246–15253. 2015.PubMed/NCBI
19	Hu L, Ai J, Long H, Liu W, Wang X, Zuo Y, Li Y, Wu Q and Deng Y: Integrative microRNA and gene profiling data analysis reveals novel biomarkers and mechanisms for lung cancer. Oncotarget. 7:8441–8454. 2016.PubMed/NCBI
20	Zhou CH, Ye LP, Ye SX, Li Y, Zhang XY, Xu XY and Gong LY: Clinical significance of SOX9 in human non-small cell lung cancer progression and overall patient survival. J Exp Clin Cancer Res. 31:182012. View Article : Google Scholar : PubMed/NCBI
21	Chaboissier MC, Kobayashi A, Vidal VI, Lützkendorf S, van de Kant HJ, Wegner M, de Rooij DG, Behringer RR and Schedl A: Functional analysis of Sox8 and Sox9 during sex determination in the mouse. Development. 131:1891–1901. 2004. View Article : Google Scholar : PubMed/NCBI
22	Akiyama H, Chaboissier MC, Martin JF, Schedl A and de Crombrugghe B: The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 16:2813–2828. 2002. View Article : Google Scholar : PubMed/NCBI
23	Müller P, Crofts JD, Newman BS, Bridgewater LC, Lin CY, Gustafsson JA and Ström A: SOX9 mediates the retinoic acid-induced HES-1 gene expression in human breast cancer cells. Breast Cancer Res Treat. 120:317–326. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lü B, Fang Y, Xu J, Wang L, Xu F, Xu E, Huang Q and Lai M: Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 130:897–904. 2008. View Article : Google Scholar : PubMed/NCBI
25	Wang H, Leav I, Ibaragi S, Wegner M, Hu GF, Lu ML, Balk SP and Yuan X: SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion. Cancer Res. 68:1625–1630. 2008. View Article : Google Scholar : PubMed/NCBI
26	Seymour PA: Sox9: A master regulator of the pancreatic program. Rev Diabet Stud. 11:51–83. 2014. View Article : Google Scholar : PubMed/NCBI
27	Jiang SS, Fang WT, Hou YH, Huang SF, Yen BL, Chang JL, Li SM, Liu HP, Liu YL, Huang CT, et al: Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 16:4363–4373. 2010. View Article : Google Scholar : PubMed/NCBI
28	Wang X, Ju Y, Zhou MI, Liu X and Zhou C: Upregulation of SOX9 promotes cell proliferation, migration and invasion in lung adenocarcinoma. Oncol Lett. 10:990–994. 2015.PubMed/NCBI
29	Capaccione KM, Hong X, Morgan KM, Liu W, Bishop JM, Liu L, Markert E, Deen M, Minerowicz C, Bertino JR, et al: Sox9 mediates Notch1-induced mesenchymal features in lung adenocarcinoma. Oncotarget. 5:3636–3650. 2014. View Article : Google Scholar : PubMed/NCBI
30	Wang X, Liu Y, Liu X, Yang J, Teng G, Zhang L and Zhou C: MiR-124 inhibits cell proliferation, migration and invasion by directly targeting SOX9 in lung adenocarcinoma. Oncol Rep. 35:3115–3121. 2016.PubMed/NCBI
31	Zhang YJ, Xu F, Zhang YJ, Li HB, Han JC and Li L: miR-206 inhibits non small cell lung cancer cell proliferation and invasion by targeting SOX9. Int J Clin Exp Med. 8:9107–9113. 2015.PubMed/NCBI
32	Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J and Yu L: miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther. 8:1773–1783. 2015. View Article : Google Scholar : PubMed/NCBI